Provided by Tiger Trade Technology Pte. Ltd.

ResMed

231.52
+3.081.35%
Post-market: 231.520.00000.00%19:30 EDT
Volume:1.73M
Turnover:399.65M
Market Cap:33.40B
PE:22.20
High:234.14
Open:229.44
Low:228.54
Close:228.44
52wk High:293.81
52wk Low:180.27
Shares:144.25M
Float Shares:143.49M
Volume Ratio:1.34
T/O Rate:1.20%
Dividend:2.40
Dividend Rate:1.04%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:5.07
PE(LYR):22.20

Loading ...

ResMed downgraded to Sector Perform from Outperform at RBC Capital

TIPRANKS
·
Jul 16

ResMed price target lowered to $220 from $235 at Mizuho

TIPRANKS
·
Jul 15

RMD or the 4% Rule? One Lets You Live Large and not Run Out of Money.

Dow Jones
·
Jul 15

Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating

MT Newswires Live
·
Jul 14

Cleveland Medical Devices: Won Favorable Ptab Outcomes in 5 of 6 Resmed Ipr Challenges

THOMSON REUTERS
·
Jul 14

Cleveland Medical Devices: in Four of Five Proceedings, Ptab Determined That Co Had not Established That Challenged Claims were Unpatentable

THOMSON REUTERS
·
Jul 14

Movement Alert|ResMed Falls 5.61% in Regular Trading, Citi Downgrades Rating to Neutral Triggering Sell-Off

Market Focus
·
Jul 13

Movement Alert|ResMed Falls 5.19% in Pre-Market Trading, Citi Downgrades Rating to Neutral

Market Focus
·
Jul 13

RMD or the 4% Rule? One Lets You Live Large and not Run Out of Money.

Dow Jones
·
Jul 13

Resmed Cut to Neutral from Buy by Citigroup

Dow Jones
·
Jul 13

3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build

Simply Wall St.
·
Jul 13

Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34

MT Newswires Live
·
Jul 13

ResMed downgraded to Neutral from Buy at Citi

TIPRANKS
·
Jul 13

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 13

RMD or the 4% Rule? One Lets You Live Large and not Run Out of Money.

Dow Jones
·
Jul 11

Resmed is Maintained at Hold by Jefferies

Dow Jones
·
Jul 11

ResMed price target lowered to $225 from $240 at Jefferies

TIPRANKS
·
Jul 10

Jefferies Adjusts Price Target on ResMed to $225 From $240

MT Newswires Live
·
Jul 10

ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan

TIPRANKS
·
Jul 10

Resmed Inc-statement of Changes in Beneficial Ownership

THOMSON REUTERS
·
Jul 10